TM6SF2 rs58542926 variant affects postprandial lipoprotein metabolism and glucose homeostasis in NAFLD

Journal of Lipid Research

Volumn 58, Issue 6, 2017, Pages 1221-1229

  Musso, Giovanni ^a   Cipolla, Ugo ^a   Cassader, Maurizio ^b   Pinach, Silvia ^a   Saba, Francesca ^a   De Michieli, Franco ^b   Paschetta, Elena ^a   Bongiovanni, Daria ^a   Framarin, Luciana ^a   Leone, Nicola ^a   Berrutti, Mara ^a   Rosina, Floriano ^c   Corvisieri, Stefania ^a   Molinaro, Federica ^a   Sircana, Antonio ^d   Gambino, Roberto ^b  

^a Medical Oncology Unit   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c Medical Team   (Italy)

^d Sassari Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; CHOLESTEROL; GASTRIC INHIBITORY POLYPEPTIDE; GLUCOSE; INCRETIN; INSULIN; LIPOPROTEIN; MEMBRANE PROTEIN; TRANSMEMBRANE 6 SUPERFAMILY MEMBER 2; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN; TM6SF2 PROTEIN, HUMAN;

ADULT; ALLELE; ARTICLE; CARDIOMETABOLIC RISK; CONTROLLED STUDY; DIET RESTRICTION; DISEASE SEVERITY; FAT TOLERANCE TEST; FATTY ACID OXIDATION; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; GLUCOSE HOMEOSTASIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERLIPIDEMIA; INDIRECT CALORIMETRY; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTESTINE TISSUE; LIPOPROTEIN METABOLISM; LIVER TISSUE; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; POSTPRANDIAL STATE; PREDICTION; PRIORITY JOURNAL; TISSUE DISTRIBUTION; GENETICS; HOMEOSTASIS; METABOLISM; PATHOPHYSIOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; FEMALE; GLUCOSE; HOMEOSTASIS; HUMANS; LIPOPROTEINS; MALE; MEMBRANE PROTEINS; NON-ALCOHOLIC FATTY LIVER DISEASE; POLYMORPHISM, SINGLE NUCLEOTIDE; POSTPRANDIAL PERIOD;

EID: 85021110907     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M075028     Document Type: Article

References (43)

1. Chalasani, N., Z. Younossi, and J. E. Lavine. 2012. The diagnosis and management of NAFLD: practice guidelines by the AASLD, ACG and the AGA. Hepatology. 55: 2005-2023.
2. Musso, G., M. Cassader, R. Gambino, and G. F. Pagano. 2011. Metaanalysis: natural history of NAFLD and diagnostic accuracy of noninvasive tests for liver disease severity. Ann. Med. 43: 617-649.
3. Schwab, U., L. Lauritzen, and T. Tholstrup. 2014. Effect of the amount and type of dietary fat on cardiometabolic risk factors and risk of developing type 2 diabetes, cardiovascular diseases, and cancer: a systematic review. Food Nutr. Res. 58: 25145.
4. Arsov, T., C. Z. Carter, and C.J. Nolan. 2006. Adaptive failure to high-fat diet characterizes steatohepatitis in Alms1 mutant mice. Biochem. Biophys. Res. Commun. 342: 1152-1159.
5. Westerbacka, J., K. Lammi, and A. M. Hakkinen. 2005. Dietary fat content modifies liver fat in overweight nondiabetic subjects. J. Clin. Endocrinol. Metab. 90: 2804-2809.
6. Kozlitina, J., and E. Smagris. 2014. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 46: 352-356.
7. Dongiovanni, P., S. Petta, C. Maglio, and A. L. Fracanzani. 2015. TM6SF2 gene variant disentangles NASH from cardiovascular disease. Hepatology. 61: 506-514.
8. Mahdessian, H., A Taxiarchis, and S. Popo. 2014. TM6SF2 is a regulator of liver fat metabolism influencing triglyceride secretion and hepatic lipid droplet content. Proc. Natl. Acad. Sci. USA. 111:8913-8918.
9. National Center for Biotechnology Information. US National Library of Medicine website. Accessed December 25, 2016, at http://wwwncbi.nlm.nih.gov/geoprofiles.
10. Holmen, O. L., H. Zhang, and Y. Fan. 2014. Systematic evaluation of coding variation identifies a candidate causal variant in TM6SF2 influencing total cholesterol and myocardial infarction risk. Nat. Genet. 46: 345-351.
11. Morris, A. P., B. F. Voight, and T. M. Teslovich. 2012. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat. Genet. 44: 981-990.
12. Musso, G., R. Gambino, and M. Cassader. 2013. Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis. Prog. Lipid Res. 52: 175-191.
13. Musso, G., E. Paschetta, R. Gambino, M. Cassader, and F. Molinaro. 2013. Interactions among bone, liver, and adipose tissue predisposing to diabesity and fatty liver. Trends Mol. Med. 19: 522-535.
14. Pirillo, A., G. D. Norata, and A. L. Catapano. 2014. Postprandial lipemia as a cardiometabolic risk factor. Curr. Med. Res. Opin. 30: 1489-1503.
15. Musso, G., M. Cassader, and S. Bo. 2013. SREBF-2 predicts 7-year NAFLD incidence and severity of liver disease and lipoprotein and glucose dysmetabolism. Diabetes. 62: 1109-1120.
16. Matsuda, M., and R A DeFronzo. 1999. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 22: 1462-1470.
17. Anstee, Q. M., A. K. Daly, and C. P. Day. 2011. Genetic modifiers of non-alcoholic fatty liver disease progression. Biochim. Biophys. Acta. 1812: 1557-1566.
18. Nuñez, C., D. Gallagher, M. Visser, and F. X. Pi-Sunyer. 1997. Bioimpedance analysis: evaluation of leg-to-leg system based on pressare contact footpad electrodes. Med. Sci. Sports Exerc. 29: 524-531.
19. Stanforth, P. R., A. S. Jackson, and J. S. Green. 2004. Generalized abdominal visceral fat prediction models for black and white adults aged 17-65 y: the HERITAGE family study. Int. J. Obes. Relat. Metab. Disord. 28: 925-932.
20. Frayn, K. N. 1983. Calculation of substrate oxidation rates in vivo from gaseous exchange. J. Appl. Physiol. 55: 628-634.
21. Ridker, P. M., and C. H. Hennekens. 1998. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet. 351: 88-92.
22. Vaidya, D., M. Szklo, and M. Cusman. 2011. Association of endothelial and oxidative stress with metabolic syndrome and subclinical atherosclerosis: multi-ethnic study of atherosclerosis. Eur. J. Clin. Nutr. 65: 818-825.
23. Cobelli, C., G. M. Toffolo, C. Dalla Man, M. Campioni, P. Denti, A. Caumo, P. Butler, and R. Rizza. 2007. Assessment of beta-cell function in humans, simultaneously with insulin sensitivity and hepatic extraction, from intravenous and oral glucose tests. Am. J. Physiol. Endocrinol. Metab. 293: E1-E15.
24. Abdul-Ghani, M. A., M. Matsuda, and B. Balas. 2007. Muscle and liver insulin resistance indexes derived from the oral glucose tolerance test. Diabetes Care. 30: 89-94.
25. Musso, G., R. Gambino, and M. Cassader. 2010. Lipoprotein metabolism mediates the association of MTP polymorphism with beta-cell dysfunction in healthy subjects and in nondiabetic normolipidemic patients with nonalcoholic steatohepatitis. J. Nutr. Biochem. 21: 834-840.
26. Abdul-Ghani, M. A., and K. Williams. 2007. What is the best predictor of future type 2 diabetes? Diabetes Care. 30: 1544-1548.
27. Thomsen, C, O. Rasmussen, and T. Lousen. 1999. Differential effects of saturated and monounsaturated fatty acids on postprandial lipemia and incretin responses in healthy subjects. Am. J. Clin. Nutr. 69: 1135-1143.
28. Daousi, C, J. P. Wilding, and S. Aditya. 2009. Effects of peripheral administration of synthetic human GIP on energy expenditure and subjective appetite sensations in healthy normal weight subjects and obese patients with type 2 diabetes. Clin. Endocrinol. (Oxf.). 71: 195-201.
29. Hansotia, T., A. Maida, and G. Flock. 2007. Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure. J. Clin. Invest. 117: 143-152.
30. Nasteska, D., N. Harada, and K. Suzuki. 2014. Chronic reduction of GIP secretion alleviates obesity and insulin resistance under high-fat diet conditions. Diabetes. 63: 2332-2343.
31. Benjamini, Y., and Y. Hochberg. 1995. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Series B Stat. Methodol. 57: 289-300.
32. Musso, G., M. Cassader, E. Paschetta, and R. Gambino. 2016. TM6SF2 may drive postprandial lipoprotein cholesterol toxicity away from the vessel walls to the liver in NAFLD. J. Hepatol. 64: 979-981.
33. Pieper-Fürst, U., and F. Lammert. 2013. LDL receptors in liver: old acquaintances and a newcomer. Biochim. Biophys. Acta. 1831: 1191-1198.
34. Llorente-Cortes, V., V. Barbarigo, and L. Badinon. 2012. LRP-1 modulates the proliferation and migration of human hepatic stellate cells. J. Cell. Physiol. 227: 3528-3533.
35. Nguyen, A., H. Tao, and M. Metrione. 2014. VLDLR expression is a determinant factor in adipose tissue inflammation and adipocytemacrophage interaction. J. Biol. Chem. 289: 1688-1703.
36. Jo, H., S. s. Choe, K. C. Shin, and H. Jang. 2013. Endoplasmic reticulum stress induces hepatic steatosis via increased expression of the hepatic VLDLR. Hepatology. 57: 1366-1377.
37. Männistö, V. T., M. Simonen, and P. Soininen. 2014. Lipoprotein subclass metabolism in nonalcoholic steatohepatitis. J. Lipid Res. 55: 2676-2684.
38. O'Hare, E. A., R. Yang, L. Yerges-Armstrong, U. Sreenivasan, R. McFarland, C. C. Leitch, M. H. Wilson, S. Narina, A. Gorden, K. Ryan, et al. TM6SF2 rs58542926 impacts lipid processing in liver and small intestine. Hepatology. Epub ahead of print. December 27, 2016; doi:
39. Liu, Y, S. Turdi, and T. Park. 2013. Adiponectin corrects high-fat diet-induced disturbances in muscle metabolomic profile and whole-body glucose homeostasis. Diabetes. 62: 743-752.
40. Lamont, B. J., and D.J. Drucker. 2008. Differential antidiabetic efficacy of incretin agonists versus DPP-4 inhibition in high fat fed mice. Diabetes. 57: 190-198.
41. Musso, G., C. Olivetti, M. Cassader, and R. Gambino. 2012. Obstructive sleep apnea-hypopnea syndrome and nonalcoholic fatty liver disease: emerging evidence and mechanisms. Semin. Liver Dis. 32: 49-64.
42. Musso, G., M. Cassader, and R. Gambino. 2016. Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies. Nat. Rev. Drug Discov. 15: 249-274.
43. Musso, G., M. Cassader, E. Paschetta, and R. Gambino. Thiazoli-dinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis of randomized trials. JAMA Intern. Med. Epub ahead of print. February 27, 2017; doi:10.1001/jamainternmed.2016.9607.